TherapeuticsMD appoints Rubric Capital partner Justin Roberts to board of directors

TherapeuticsMD, Inc.

Justin Roberts, Partner at Rubric Capital Management, appointed to fill newly created Board seat effective Aug. 23, 2022.
Board size increased to nine directors; Roberts will stand for election at 2022 Annual Meeting.
Rubric recently invested $15M in TherapeuticsMD via private placement of Series A Preferred and common stock (July 29, 2022).
Roberts has elected not to receive any director compensation at this time.
No other arrangements or material transactions between Roberts and Company beyond the Rubric investment.

item 5.02 item 1.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Justin Roberts

Director

TXMD · TherapeuticsMD, Inc.

Effective: 2022-08-23
Filed: August 29, 2022, 7:59 PM ET

On and effective as of August 23, 2022, the board of directors (the “Board”) of TherapeuticsMD, Inc., a Nevada corporation (the “Company”), appointed Mr. Justin Roberts as a director to fill a newly created vacancy on the Board as a result of the Board’s increase in the size of the Board by one director to a total of nine directors.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Justin Roberts was appointed as Director at TherapeuticsMD, Inc..

Action: appointed
Role: Director

Exact text from the filing

On and effective as of August 23, 2022, the board of directors (the “Board”) of TherapeuticsMD, Inc., a Nevada corporation (the “Company”), appointed Mr. Justin Roberts as a director to fill a newly created vacancy on the Board as a result of the Board’s increase in the size of the Board by one director to a total of nine directors.

View on SEC.gov

TherapeuticsMD, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-232894

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.